TY - JOUR
T1 - SP-D loaded PLGA nanoparticles as drug delivery system for prevention and treatment of premature infant's lung diseases
AU - Attias Cohen, Shani
AU - Kingma, Paul S.
AU - Whitsett, J. A.
AU - Goldbart, Riki
AU - Traitel, Tamar
AU - Kost, Joseph
N1 - Funding Information:
We wish to thank Dr. Einat Nativ-Ruth (Ilse Katz Institute for Nanoscale Science and Technology) for her assistance in HR- SEM analysis. This work was financially supported by BG3C binational fund ( RD2012-0801 ) of Ben Gurion University and Cincinnati Children’s Hospital Medical Center (CCHC).
Publisher Copyright:
© 2020 Elsevier B.V.
PY - 2020/7/30
Y1 - 2020/7/30
N2 - Preterm infants, particularly those who born between 23 and 28 weeks’ gestation, suffer from a very high incidence of respiratory distress syndrome (RDS) related to pulmonary immaturity and inability to make Pulmonary Surfactant (PS). These infants are supported by the use of oxygen, ventilators, and routine administration of surfactant replacement. The currently commercial surfactant replacement therapies do not contain hydrophilic surfactant proteins such as Surfactant Protein D (SP-D). These proteins have a key role in the innate lung host defense, thus the development of a sustained release vehicle that provides SP-D for long periods in preterm infants’ lungs would exploit the therapeutic potential of SP-D and other pulmonary medications. The proposed SP-D delivery system is based on nanoparticles (NPs) composed of poly (lactic acid-co-glycolic acid) (PLGA), a biodegradable, FDA approved biopolymer. The resulted NPs were spherical with high Zeta potential value, were not toxic to A-549 lungs cells, and did not induce any inflammatory response in mouse's lungs for short and long-term periods. Moreover, SP-D released from NPs showed biological activity for several days and in vivo release experiment of SP-D loaded NPs revealed that SP-D was released from NPs in mouse lungs with different NPs delivery doses.
AB - Preterm infants, particularly those who born between 23 and 28 weeks’ gestation, suffer from a very high incidence of respiratory distress syndrome (RDS) related to pulmonary immaturity and inability to make Pulmonary Surfactant (PS). These infants are supported by the use of oxygen, ventilators, and routine administration of surfactant replacement. The currently commercial surfactant replacement therapies do not contain hydrophilic surfactant proteins such as Surfactant Protein D (SP-D). These proteins have a key role in the innate lung host defense, thus the development of a sustained release vehicle that provides SP-D for long periods in preterm infants’ lungs would exploit the therapeutic potential of SP-D and other pulmonary medications. The proposed SP-D delivery system is based on nanoparticles (NPs) composed of poly (lactic acid-co-glycolic acid) (PLGA), a biodegradable, FDA approved biopolymer. The resulted NPs were spherical with high Zeta potential value, were not toxic to A-549 lungs cells, and did not induce any inflammatory response in mouse's lungs for short and long-term periods. Moreover, SP-D released from NPs showed biological activity for several days and in vivo release experiment of SP-D loaded NPs revealed that SP-D was released from NPs in mouse lungs with different NPs delivery doses.
KW - Controlled release
KW - Drug delivery
KW - Nanoparticles
KW - Poly(lactic acid-co-glycolic acid) (PLGA)
KW - Respiratory Distress Syndrome
KW - Surfactant protein D
UR - http://www.scopus.com/inward/record.url?scp=85086746956&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2020.119387
DO - 10.1016/j.ijpharm.2020.119387
M3 - Article
C2 - 32473376
AN - SCOPUS:85086746956
SN - 0378-5173
VL - 585
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 119387
ER -